{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:01:48Z","timestamp":1780470108957,"version":"3.54.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, neurological immune-related adverse events (n-irAEs) associated with these agents are increasingly recognized. However, kelch-like protein-11(KLHL11)-IgG cerebellitis has not been reported as an n-irAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a case of a 53-year-old man with lung adenocarcinoma treated with tislelizumab who developed KLHL11-IgG cerebellitis. First-line immunotherapy, comprising intravenous methylprednisolone and immunoglobulin, failed to improved his symptoms. Subsequent administration of efgartigimod (10 mg\/kg weekly for 4 doses) led to seroconversion of KLHL11-IgG and marked clinical recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first report of efgartigimod as a successful rescue therapy for isolated ICI-related KLHL11-IgG cerebellitis. These findings support efgartigimod as a promising treatment option for this condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1864182","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:42Z","timestamp":1780466742000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi-Xiao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, Ningbo Taikang Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Mian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Ningbo Taikang Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: Illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15624","article-title":"Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review","volume":"30","author":"Dinoto","year":"2023","journal-title":"Eur J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200218","article-title":"Immune checkpoint inhibitor-associated kelch-like protein-11 IgG brainstem encephalitis","volume":"11","author":"Aboseif","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1212\/WNL.0000000000208623","article-title":"84-year-old male with kelch-like protein 11 (KLHL11) antibody-associated rhombencephalitis and Merkel cell carcinoma (P3-8.013)","volume":"104","author":"Swaminathan","year":"2025","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109074","article-title":"Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome: A state-of-the-art review","volume":"241","author":"Li","year":"2022","journal-title":"Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1613070","article-title":"Case report: KLHL11 encephalitis in a female patient with dual primary Malignancies of breast and lung cancer: Response to FcRn inhibitor therapy","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1056\/NEJMoa1816721","article-title":"Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis","volume":"381","author":"Mandel-Brehm","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15758","article-title":"Anti-kelchlike protein 11 antibody-associated encephalitis: Two case reports and review of the literature","volume":"30","author":"Le\u00f3n Betancourt","year":"2023","journal-title":"Eur J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab185","article-title":"Immunopathogenesis and proposed clinical score for identifying kelch-like protein-11 encephalitis","volume":"3","author":"Vogrig","year":"2021","journal-title":"Brain Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1640281","article-title":"Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: First case report","volume":"16","author":"Tu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:43Z","timestamp":1780466743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2026.1864182"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1864182","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1864182"}}